Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) will release its third quarter 2025 financial results for the period ended September 30, 2025 on Monday, November 10, 2025 prior to market open.
The company will host a conference call on November 10, 2025 at 8:00 a.m. EST to discuss results and recent business highlights. Investors are asked to register for dial‑in details and to dial in 15 minutes early to avoid delays. A live webcast and an online archive will be available in the Investors section at https://ir.akebia.com/.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AKBA declined NaN%, reflecting a moderate negative market reaction. Argus tracked a peak move of +5.5% during that session. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Akebia to Host Conference Call on November 10, 2025, at 8:00 a.m. EST
CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, prior to the open of financial markets.
Akebia will host a conference call on Monday, November 10, 2025, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at https://akebia.com/, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When will Akebia (AKBA) report Q3 2025 results?
What time is the Akebia (AKBA) conference call on November 10, 2025?
How can investors access the Akebia (AKBA) Q3 2025 webcast?
Do I need to register to join the Akebia (AKBA) conference call on November 10, 2025?
Will the Akebia (AKBA) conference call be archived for later viewing?
